BRCA2 c.156_157insAlu Founder Variant in Northern Portugal: An Insight Into Hereditary Breast and Ovarian Cancer Genetic Risk and Management
Clinical Genetics · 2026
DOI: 10.1111/cge.70046 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Genetics, 2026. Verfasst von Sílvia A C Duarte und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Local Health Unit Trás-os-Montes and Alto Douro, Vila Real, Portugal. Hauptthemen laut MEDLINE: BRCA2 Protein, Genetic Predisposition to Disease, Hereditary Breast and Ovarian Cancer Syndrome, Founder Effect. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Fundação para a Ciência e a Tecnologia.
Abstract (Originalsprache)
The BRCA2 c.156_157insAlu variant is a Portuguese founder mutation implicated in hereditary breast and ovarian cancer (HBOC). This study aims to determine its occurrence and clinical implications in the northern interior region of Portugal. A retrospective study of 571 individuals referred for HBOC genetic counseling and testing between 2021 and 2024 was conducted. Genetic screening was performed using next‐generation sequencing of 27 hereditary cancer genes, with confirmatory PCR for BRCA2 c.156_157insAlu. Pathogenic or likely pathogenic variants were detected in 19.8% of participants, with BRCA1/2 variants accounting for 5.4%. The BRCA2 c.156_157insAlu variant was identified in 6 individuals (25% of all BRCA2 pathogenic variants identified), including breast cancer patients and asymptomatic carriers. Clinically, it was associated with early onset and contralateral breast cancer. Cascade testing and genetic counseling were offered to at‐risk relatives. The BRCA2 c.156_157insAlu variant remains a significant contributor to HBOC in northern Portugal. Its high local proportion among BRCA2 variants supports the implementation of targeted genetic testing strategies, enhancing early detection and personalized cancer risk management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology Department, Local Health Unit Trás-os-Montes and Alto Douro, Vila Real, Portugal.
- CECAV, School of Agrarian and Veterinary Sciences, University of Trás-os-Montes and Alto Douro (UTAD), Vila Real, Portugal.
- Genetics Laboratory, Local Health Unit Trás-os-Montes and Alto Douro, Vila Real, Portugal.
- Genetic Consultation, Local Health Unit Trás-os-Montes and Alto Douro, Vila Real, Portugal.
- Maternal and Child Department, Local Health Unit Trás-os-Montes and Alto Douro, Vila Real, Portugal.
ORCID-Profile: Sílvia A C Duarte, Regina Arantes, Márcia Martins, Felisbina L Queiroga, Rosário Pinto-Leite
Förderung
- Fundação para a Ciência e a Tecnologia
Zitieren
APA
Duarte, S. A. C., Arantes, R., Martins, M., Moutinho, O., Queiroga, F. L., & Pinto-Leite, R. (2026). BRCA2 c.156_157insAlu Founder Variant in Northern Portugal: An Insight Into Hereditary Breast and Ovarian Cancer Genetic Risk and Management. Clinical Genetics. https://doi.org/10.1111/cge.70046
Vancouver
Duarte SAC, Arantes R, Martins M, Moutinho O, Queiroga FL, Pinto-Leite R. BRCA2 c.156_157insAlu Founder Variant in Northern Portugal: An Insight Into Hereditary Breast and Ovarian Cancer Genetic Risk and Management. Clinical Genetics. 2026. doi:10.1111/cge.70046
BibTeX
@article{Duarte2026,
author = {Duarte, Sílvia A C and Arantes, Regina and Martins, Márcia and Moutinho, Osvaldo and Queiroga, Felisbina L and Pinto-Leite, Rosário},
title = {BRCA2 c.156_157insAlu Founder Variant in Northern Portugal: An Insight Into Hereditary Breast and Ovarian Cancer Genetic Risk and Management},
journal = {Clinical Genetics},
year = {2026},
doi = {10.1111/cge.70046}
}
EUVIMED